September 20, 2021
FDA committee votes against COVID-19 vaccine boosters for general population
Editor's Note
The Food and Drug Administration’s (FDA’s) Vaccines and Related Biological Products Advisory Committee on September 17 voted that there was not enough safety and effectiveness data to approve a third Pfizer COVID-19 vaccine dose for those 16 years and older.
The committee did vote to recommend approval of a booster dose for people 65 years and older and those at high risk of severe COVID-19.
The committee also recommended approval of a booster for those with occupational risks, such as healthcare workers and teachers.
Free Daily News
- 7 strategies healthcare leaders can use to turn around toxic workplace culture
- Nutrition screening tool predicts poor outcomes after pancreatic cancer surgery
- CDC reports 460% surge in drug-resistant NDM-CRE infections
- 5 reasons why perioperative leaders deserve to attend the 2025 OR Manager Conference
- Global medical community rejects Trump’s Tylenol-autism claims: Statements compilation
- Surgery, implantable devices offer new hope for drug-resistant epilepsy
- Remote monitoring speeds recovery, lowers complications after cancer surgery
- Common supplements may heighten bleeding risk during surgery, Polish study finds
- Keeping sensory aids in place during surgery reduces delirium risk in older hip fracture patients
- HFMA warns affordability crisis is driving up provider bad debt
© Access Intelligence, LLC. All rights reserved. |
Privacy Policy |
Cookie Settings |
Diversity, Equity, Inclusion & Belonging |
Accessibility Statement